RenovoRx (NASDAQ:RNXT) Given New $8.25 Price Target at Ascendiant Capital Markets

RenovoRx (NASDAQ:RNXT) had its price target lifted by Ascendiant Capital Markets from $8.00 to $8.25 in a report published on Thursday, Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

RenovoRx Stock Performance

Shares of NASDAQ RNXT opened at $1.13 on Thursday. RenovoRx has a 52 week low of $0.53 and a 52 week high of $2.35. The stock’s fifty day moving average is $1.13 and its 200 day moving average is $1.24.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.10) EPS for the quarter.

Institutional Trading of RenovoRx

An institutional investor recently bought a new position in RenovoRx stock. Nixon Peabody Trust Co. acquired a new position in RenovoRx, Inc. (NASDAQ:RNXT) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 97,165 shares of the company’s stock, valued at approximately $223,000. Nixon Peabody Trust Co. owned 0.91% of RenovoRx at the end of the most recent reporting period. 3.10% of the stock is currently owned by institutional investors.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.